Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retrospective cohort study assessing safety and prognostic value of Regadenoson Stress Cardiac Magnetic Resonance Imaging in Heart Transplant Recipients

Trial Profile

Retrospective cohort study assessing safety and prognostic value of Regadenoson Stress Cardiac Magnetic Resonance Imaging in Heart Transplant Recipients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Regadenoson (Primary)
  • Indications Coronary disorders
  • Focus Adverse reactions; Diagnostic use; Therapeutic Use
  • Most Recent Events

    • 15 Dec 2018 New trial record
    • 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top